Hvor estimeret 97% (93%) af patienterne med CCyR (PCyR) ved 12 måneder var fri for progression til accelereret fase/ blastkrise ved 60 måneder, var kun 81% af patienterne uden CCyR ved 12 måneder fri for progression til fremskreden CML ved 60 måneder 63 (p < 0, 001 samlet, p=0, 20 mellem CCyR og PCyR).
Whereas an estimated 97% (93%) of patients with CCyR (PCyR) at 12 months were free of progression to accelerated phase/ blast crisis at 60 months, only 81% of patients without MCyR at 12 months were free of progression to advanced CML at 60 months (p < 0.001 overall, p=0.20 between CCyR and PCyR).